Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Health
Biotech
STAT+
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

FDA rejects Intarcia’s diabetes implant for a second time

  • Kate Sheridan

By Kate Sheridan March 10, 2020

Reprints
insulin biosimilar
Jacquelyn Martin/AP

For the second time, the Food and Drug Administration rejected an Intarcia Therapeutics implant aimed at treating type 2 diabetes, the company said Tuesday.

“We are extremely disappointed,” Intarcia spokesperson Sunny Uberoi told STAT in a statement. “We remain steadfast in our belief that [the implant] holds important potential as a new treatment option for people managing type 2 diabetes.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Kate Sheridan

Kate Sheridan

Research Reporter

Kate collects and analyzes documents, data, and other information for biotech, health tech, science, and politics stories.

Tags

Texas judge strikes down major Obamacare provision protecting preventive…
Texas judge strikes down major Obamacare provision protecting preventive care
The history of OxyContin, told through unsealed Purdue documents
The history of OxyContin, told through unsealed Purdue documents
New on the streets: Gabapentin, a drug for nerve…
New on the streets: Gabapentin, a drug for nerve pain, and a new target of misuse
Drug middlemen switch tactics, but the outcome is the…
Drug middlemen switch tactics, but the outcome is the same: high prices
Listen: Biotech’s monkey shortage, the broken generics market, &…
Listen: Biotech’s monkey shortage, the broken generics market, & conference cancel culture
FDA proposes a new plan to streamline updates to…
FDA proposes a new plan to streamline updates to medical devices that use AI

Recommended Stories